Oppenheimer analyst Leland Gershell downgraded Essa Pharma (EPIX) to Perform from Outperform without a price target The company announced that it will discontinue all masofaniten development following a prespecified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study, the analyst tells investors in a research note. The firm awaits details as Essa moves to a strategic process in which it will explore options that can maximize shareholder value.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EPIX:
- Essa Pharma downgraded to Hold from Buy at Jefferies
- Essa Pharma downgraded to Hold from Buy at JonesResearch
- Essa Pharma terminates Phase 2 study of masofaniten combo in mCRPC
- Essa Pharma presents updated updated Phase 1/2 masofaniten data at ESMO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
